ZeptoMetrix® announces the immediate availability of it’s ready-to-use, NATtrol™ inactivated, whole intact SARS-CoV-2 molecular quality control – NATSARS(COV2)-ERC – for laboratory QC and test validation.
BUFFALO, N.Y. (PRWEB) MAY 05, 2020
Continuing in its efforts to rapidly respond to today’s COVID-19 pandemic, ZeptoMetrix Corporation (ZMC)announced today the development and release of a ready-to-use SARS-CoV-2 molecular quality control formulated with purified intact viral particles that have been chemically modified to render them non-infectious and refrigerator stable:
- NATtrol SARS-CoV-2 Positive Control
- Product Number: NATSARS(COV2)-ERC
Complementing the release of the positive control is a negative control formulated with human A549 cells:
- NATtrol SARS-CoV-2 Negative Control
- Product Number: NATSARS(COV2)-NEG
“Due to the unprecedented COVID-19 pandemic, we were tasked to develop and deploy reliable, user-friendly commercial solutions for ready-to-use, non-infectious SARS-CoV-2 full process molecular quality controls under accelerated timelines. Today, I am extremely proud to announce that ZeptoMetrix has launched such controls – containing purified intact viral particles of actual SARS-CoV-2 that provide laboratories, hospitals and research facilities with essential external run controls to help ensure the reliability of COVID-19 testing”, explains Shawn R. Smith, President & CEO of ZeptoMetrix.
“In conjunction with our existing and ever expanding product portfolio, we recognize the responsibility embodied by our company’s ability to meet today’s challenges and to positively impact public health efforts by leveraging the many capabilities we possess. From initial sourcing of the virus to carefully controlled processing in containment labs and through the array of technical, operational and logistical resources deployed against this endeavor, our company rose to the challenge by displaying the commitment and perseverance required to succeed, especially in these challenging times.”
Today more than ever, it is critical to global healthcare that we have a more complete understanding of Infectious Diseases and the diagnostic technologies employed in their testing. ZeptoMetrix has enhanced its coronavirus product line and has made it a priority to ensure product availability to diagnostic companies developing new and improved tests as well as those laboratories in hospitals and clinics seeking to ensure the reliability of the tests they perform.
NATtrol SARS-CoV-2 Positive Control – NATSARS(COV2)-ERC
NATtrol SARS-CoV-2 Negative Control – NATSARS(COV2)-NEG
NATtrol SARS-CoV-2 Stock – NATSARS(COV2)-ST
SARS-CoV-2 Isolate: USA-WA1/2020 Heat Inactivated Culture Fluid – 0810587CFHI-0.5ML
SARS-CoV-2 Isolate: USA-WA1/2020 Heat Inactivated Culture Fluid – 0810587CFHI
NATtrol Coronavirus SARS Stock – NATSARS-ST
NATtrol Coronavirus 229E Stock – NATCOV(229E)-ST
Coronavirus Strain: 229E Culture Fluid – 0810229CF
Coronavirus Strain: 229E Heat Inactivated Culture Fluid – 0810229CFHI
Coronavirus Strain: 229E Lysate – 0810229
NATtrol Coronavirus NL63 Stock – NATCOV(NL63)-ST
Coronavirus Strain: NL63 Culture Fluid – 0810228CF
Coronavirus Strain: NL63 Heat Inactivated Culture Fluid – 0810228CFHI
Coronavirus Strain: NL63 Lysate – 0810228
NATtrol Coronavirus OC43 Stock – NATCOV(OC43)-ST
Coronavirus Strain: OC43 Culture Fluid – 0810024CF
Coronavirus Strain: OC43 Heat Inactivated Culture Fluid – 0810024CFHI
Coronavirus Strain: OC43 Lysate – 0810024
MERS-CoV Florida/USA-2_Saudi Arabia_2014
NATtrol MERS-CoV Stock – NATMERS-ST
MERS-CoV Strain: Florida/USA-2_Saudi Arabia_2014 Culture Fluid – 0810575CF
MERS-CoV Strain: Florida/USA-2_Saudi Arabia_2014 Heat Inactivated Culture Fluid – 0810575CFHI
ZeptoMetrix Corporation (ZMC) is an established industry leader in the design, development, and delivery of innovative, quality solutions to the Infectious Disease Diagnostics Market. Our expertise and abilities in Molecular Diagnostics, including External Quality Controls, Verification Panels, Proficiency Panels, Customized and OEM Products/Services have set the industry standard for performance and reliability and made ZeptoMetrix the preferred choice for independent 3rd party QC materials.
Founded in 1999, ZeptoMetrix is headquartered in Buffalo, NY with additional facilities in Franklin, Massachusetts.
Globally, millions of people are tested for infectious diseases each year. The implications of reporting either a false positive or a false negative can be devastating to the patient. Accurate and sensitive diagnostics are necessary to confirm that laboratories are providing patients with proper testing results. Utilizing ZeptoMetrix NATtrol QC materials on a consistent basis helps to monitor testing performance and enhance confidence in testing results.
ZeptoMetrix NATtrol Molecular Diagnostics products are an essential component of today’s ever-evolving testing market and are designed to provide safe, accurate and cost-effective support for activities relating to the analysis and identification of possible disease-causing microorganisms. The patented ZeptoMetrix NATtrol process renders highly-purified microorganisms non-infectious while allowing internal nucleic acids to remain intact, thereby serving as an ideal reference material for molecular diagnostic testing applications. Representing a total process control, from DNA extraction through amplification and eventual detection, NATtrol products are ready-to-use, refrigerator stable, and safe for operators to handle.
The routine and repetitive use of NATtrol™ External Run Controls and Verification Panels help enable laboratories to monitor performance and identify trends in daily test variations, test kit lot changes, and among individual operators.
For Sales and/or information regarding ZeptoMetrix, NATtrol Molecular Quality Controls & Panels, and Development/Custom Services, please contact ZeptoMetrix Customer Service.
ZeptoMetrix Corporation, Customer Service
878 Main Street
Buffalo, NY 14202
Michael Hershfield, Vice President, Sales & Marketing
“Due to the unprecedented COVID-19 pandemic, we were tasked to develop and deploy reliable, user-friendly commercial solutions for ready-to-use, non-infectious SARS-CoV-2 full process molecular quality controls under accelerated timelines.”